Robyn Karnauskas
Stock Analyst at Truist Securities
(2.46)
# 2,437
Out of 5,241 analysts
177
Total ratings
43.42%
Success rate
0.63%
Average return
Main Sectors:
Stocks Rated by Robyn Karnauskas
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LLY Eli Lilly and Company | Maintains: Buy | $1,038 → $1,182 | $1,006.70 | +17.41% | 6 | Nov 19, 2025 | |
| ABCL AbCellera Biologics | Maintains: Buy | $28 → $10 | $4.40 | +127.27% | 2 | May 16, 2025 | |
| AMGN Amgen | Maintains: Hold | $333 → $298 | $336.23 | -11.37% | 12 | Jan 8, 2025 | |
| BMY Bristol-Myers Squibb Company | Maintains: Buy | $62 → $65 | $56.77 | +14.50% | 2 | Jan 8, 2025 | |
| MRK Merck & Co. | Downgrades: Hold | $130 → $110 | $113.41 | -3.01% | 11 | Jan 8, 2025 | |
| GILD Gilead Sciences | Maintains: Hold | $82 → $83 | $132.06 | -37.15% | 18 | Aug 15, 2024 | |
| ABBV AbbVie | Reiterates: Buy | $195 → $210 | $210.77 | -0.37% | 8 | Jul 26, 2024 | |
| BMEA Biomea Fusion | Downgrades: Hold | n/a | $1.43 | - | 3 | Jun 11, 2024 | |
| BIIB Biogen | Maintains: Buy | $340 | $191.37 | +77.67% | 17 | May 16, 2024 | |
| CRIS Curis | Maintains: Buy | $26 | $0.51 | +4,965.26% | 2 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $8 → $7 | $1.63 | +329.45% | 13 | May 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $1,135 | $712.87 | +59.22% | 16 | Apr 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $10 | $2.19 | +356.62% | 2 | Mar 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $9 | $5.54 | +62.45% | 4 | Mar 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $23 | $29.50 | -22.03% | 5 | Mar 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $48 | $28.96 | +65.75% | 5 | Mar 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $50 | $24.95 | +100.40% | 8 | Mar 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $456 → $508 | $450.41 | +12.79% | 13 | Jan 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $42 → $36 | $25.75 | +39.81% | 5 | Dec 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $25 | $72.72 | -65.62% | 1 | Oct 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $1.21 | - | 6 | Oct 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $140 | $53.24 | +162.96% | 5 | Sep 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $30,000 | $1.98 | +1,515,051.52% | 2 | Sep 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Hold | $7 | $1.90 | +268.42% | 3 | Aug 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $65 → $55 | $27.75 | +98.20% | 1 | May 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $500 → $320 | $8.05 | +3,877.63% | 2 | Aug 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $10 → $15 | $38.70 | -61.24% | 5 | Aug 9, 2022 |
Eli Lilly and Company
Nov 19, 2025
Maintains: Buy
Price Target: $1,038 → $1,182
Current: $1,006.70
Upside: +17.41%
AbCellera Biologics
May 16, 2025
Maintains: Buy
Price Target: $28 → $10
Current: $4.40
Upside: +127.27%
Amgen
Jan 8, 2025
Maintains: Hold
Price Target: $333 → $298
Current: $336.23
Upside: -11.37%
Bristol-Myers Squibb Company
Jan 8, 2025
Maintains: Buy
Price Target: $62 → $65
Current: $56.77
Upside: +14.50%
Merck & Co.
Jan 8, 2025
Downgrades: Hold
Price Target: $130 → $110
Current: $113.41
Upside: -3.01%
Gilead Sciences
Aug 15, 2024
Maintains: Hold
Price Target: $82 → $83
Current: $132.06
Upside: -37.15%
AbbVie
Jul 26, 2024
Reiterates: Buy
Price Target: $195 → $210
Current: $210.77
Upside: -0.37%
Biomea Fusion
Jun 11, 2024
Downgrades: Hold
Price Target: n/a
Current: $1.43
Upside: -
Biogen
May 16, 2024
Maintains: Buy
Price Target: $340
Current: $191.37
Upside: +77.67%
Curis
May 15, 2024
Maintains: Buy
Price Target: $26
Current: $0.51
Upside: +4,965.26%
May 13, 2024
Maintains: Buy
Price Target: $8 → $7
Current: $1.63
Upside: +329.45%
Apr 3, 2024
Maintains: Buy
Price Target: $1,135
Current: $712.87
Upside: +59.22%
Mar 26, 2024
Maintains: Buy
Price Target: $10
Current: $2.19
Upside: +356.62%
Mar 26, 2024
Maintains: Buy
Price Target: $9
Current: $5.54
Upside: +62.45%
Mar 25, 2024
Reiterates: Buy
Price Target: $23
Current: $29.50
Upside: -22.03%
Mar 25, 2024
Reiterates: Buy
Price Target: $48
Current: $28.96
Upside: +65.75%
Mar 25, 2024
Reiterates: Buy
Price Target: $50
Current: $24.95
Upside: +100.40%
Jan 31, 2024
Maintains: Buy
Price Target: $456 → $508
Current: $450.41
Upside: +12.79%
Dec 14, 2023
Maintains: Buy
Price Target: $42 → $36
Current: $25.75
Upside: +39.81%
Oct 6, 2023
Downgrades: Hold
Price Target: $25
Current: $72.72
Upside: -65.62%
Oct 5, 2023
Downgrades: Hold
Price Target: n/a
Current: $1.21
Upside: -
Sep 25, 2023
Reiterates: Buy
Price Target: $140
Current: $53.24
Upside: +162.96%
Sep 6, 2023
Reiterates: Buy
Price Target: $30,000
Current: $1.98
Upside: +1,515,051.52%
Aug 16, 2023
Reiterates: Hold
Price Target: $7
Current: $1.90
Upside: +268.42%
May 11, 2023
Maintains: Buy
Price Target: $65 → $55
Current: $27.75
Upside: +98.20%
Aug 23, 2022
Maintains: Buy
Price Target: $500 → $320
Current: $8.05
Upside: +3,877.63%
Aug 9, 2022
Maintains: Buy
Price Target: $10 → $15
Current: $38.70
Upside: -61.24%